Company newsMRNA
Explain this story: Moderna Stock Reached New 52-Week High: What's Happening?
Moderna (NASDAQ: MRNA) shares reached a new 52-week high of $198 due to anticipation surrounding upcoming clinical trial data for its experimental cancer treatment, intismeran autogene. The company's headline abstract on late-stage trial results for intismeran combined with Merck's Keytruda in melanoma patients has been accepted for the European Society for Medical Oncology Congress. Despite the rally and promising trial results, Bernstein SocGen Group maintained a "Market Perform" rating and a $45 price target, expressing skepticism about the stock's current valuation.
OtherBenzingaSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Moderna (NASDAQ: MRNA) shares reached a new 52-week high of $198 due to anticipation surrounding upcoming clinical trial data for its experimental cancer treatment, intismeran autogene. The company's headline abstract on late-stage trial results for intismeran combined with Merck's Keytruda in melanoma patients has been accepted for the European Society for Medical Oncology Congress. Despite the rally and promising trial results, Bernstein SocGen Group maintained a "Market Perform" rating and a $45 price target, expressing skepticism about the stock's current valuation.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Also mentioned:MRK
Published Sep 25, 2026, 12:13 ET · on this site +1d 13h